|
Video: What is a Stock Split?
|
|
Roivant Sciences develops drug candidates in subsidiary companies Co. calls Vants. Co.'s Vants and pipeline include Dermavant Sciences Ltd., which is developing tapinarof for the treatment of psoriasis and atopic dermatitis, with an earlier-stage development pipeline; Immunovant, Inc., which is developing IMVT-1401 for the treatment of Myasthenia Gravis, Warm Autoimmune Hemolytic Anemia and Thyroid Eye Disease; Aruvant Sciences Ltd., which is developing ARU-1801 as a one-time, potentially curative gene therapy for the treatment of sickle cell disease; and Proteovant Sciences, Inc, which is developing heterobifunctional protein degraders for oncology, neurology, and immunology AR Degrader. According to our ROIV split history records, Roivant Sciences has had 0 splits. | |
|
Roivant Sciences (ROIV) has 0 splits in our ROIV split history database.
Looking at the ROIV split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Roivant Sciences shares, starting with a $10,000 purchase of ROIV, presented on a split-history-adjusted basis factoring in the complete ROIV split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
12/09/2020 |
|
End date: |
03/28/2024 |
|
Start price/share: |
$9.96 |
|
End price/share: |
$10.54 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
5.82% |
|
Average Annual Total Return: |
1.73% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$10,582.09 |
|
Years: |
3.30 |
|
|
|
|
|